Current risk stratification models for MGUS/Smoldering Multiple Myeloma (SMM) increasingly incorporate inflammatory and metabolic biomarkers, with our findings supporting CXCL10 and IL‐6 as potential candidates for dynamic monitoring [22, 23, 34]. Here, IL6 is linked to plasma cell myeloma.